AstraZeneca

CytoSorbents submits DrugSorb™-ATR De Novo marketing application to FDA for priority review as a Breakthrough Device, aiming to reduce perioperative bleeding in CABG patients on ticagrelor. Health Canada MDL application pending MDSAP certification. Regulatory decisions expected in 2025.

The FDA approved the first self-administered flu vaccine, FluMist, which can be given by a caretaker for those under 18. Experts hope this will increase vaccination rates, as it allows for home delivery and avoids shots.

FDA approves FluMist for self- or caregiver-administration, the first influenza vaccine not requiring a health care professional. Available for ages 2-49, it can be self-administered or by a caregiver aged 18+ via a third-party online pharmacy.

FDA approves FluMist, a nasal spray flu vaccine for self-administration, for healthy individuals aged 2 to 49. FluMist effectiveness is comparable to the flu shot and protects against severe flu complications. Administered at home via a spray in each nostril, it may have side effects like runny nose and fever. Cost and insurance coverage for the at-home version are uncertain, with availability starting next flu season.

August 2024 biopharma deals highlight trends in bispecific T-cell engagers, CD-19 targeting in autoimmune diseases, and Chinese biopharma innovation. Merck's $1.3B acquisition of Curon's CD3xCD19 BiTE CN201 reflects confidence in early trial outcomes and market enthusiasm for BiTEs. JPMorgan reports a 50% reduction in upfront payments since 2020, indicating a more back-loaded deal structure.

Fred Hutch study shows industry-sponsored cancer trials enroll 8 times more patients than federally funded ones, with a growing reliance on industry. Federally funded trials, crucial for health equity and diverse demographics, face underinvestment, despite their significant contributions to clinical care. Both funding sources are vital for advancing cancer research.

FDA approves Tagrisso® (osimertinib) for stage III, unresectable EGFR-mutated NSCLC not progressed post-CRT, based on LAURA trial showing 84% reduced risk of disease progression with osimertinib vs placebo (median PFS 39.1 vs 5.6 months).

The biocompatible polymers market, valued at USD 957 million in 2023, is projected to reach USD 1,847.7 million by 2033, driven by healthcare advancements, particularly in medical implants, drug delivery systems, and tissue engineering. North America leads the market, while Asia-Pacific is expected to grow significantly. Key applications include medical devices, drug delivery systems, tissue engineering, and prosthetics. Biodegradable polymers are expanding the market's scope. Evonik Industries AG is the largest vendor.

Mike Peters, frontman of The Alarm, diagnosed with aggressive Richter’s syndrome, saw his cancer disappear after participating in a clinical trial combining acalabrutinib with chemotherapy at The Christie NHS Foundation Trust. Now in complete remission, he plans to undergo a donor stem cell transplant for a chance at a cure.

Innate Pharma SA will co-host a hybrid scientific symposium on October 3, 2024, with Mount Sinai, featuring key opinion leaders in immunotherapy. The event marks Innate Pharma's 25th anniversary and highlights next-generation immunotherapy discoveries.